Remus Pharmaceuticals IPO Particulars & Guidance at,
    the Oldest & the most Trusted Investment Website in India for coming up IPOs. Operational since 8th December 1999, this is the Only Investment Platform in India, which has successfully completed 23 Years.

    Remus Pharmaceuticals Listing Estimate:
    The IPO received strong response and also there is steady fancy in the grey market. The IPO is expected to get listed around Rs. 1800.
    Actual Listing at Rs. 1711.25

    Remus Pharmaceuticals IPO Review:
    There is sudden rise in the turnover and profits in the year just prior to the IPO and we cannot comment whether such profits will continue in future or not. This is mainly a trading company and has no niche business. However, the IPO has fancy in the grey market and only from that angle, you may apply this IPO.


    What is the GMP of Remus Pharmaceuticals IPO?GMP prior to listing
    GMP Rs. 55
    Allotted Application Rate Rs.50000

    Remus Pharmaceuticals IPO Subscription Status
    On 19 May 2023 @ 5.00 (closed)
    QIB:     138750 Shares  10.75  T
    NII:      41625   Shares  229.29 T
    RII:      97125   Shares  49.53 T
    Total:   277500 Shares  57.11  T

    Remus Pharmaceuticals IPO Particulars & Guidance:
    About the business

    The company is engaged in the marketing and distributing of finished formulations of pharmaceutical drugs.

    The product offerings of the company can be classified into two major categories:

    1. APIs: Active Pharmaceutical Ingredient (API) is the biologically active component of a drug product (tablet, capsule, cream, injectable) that produces the intended effects.
    2. Finished Pharmaceutical Formulations: Finished pharmaceutical formulations are therapeutic drugs available in different dosage forms.

    Get more information about the company @

    Remus Pharmaceuticals IPO Details
    IPO opens on Tentative  17 May 2023
    IPO closes on   19 May 2023
    Issue Type Book Built Issue IPO
    Issue Size 388000 Sh /Rs 47.69 Cr
    * Fresh Issue 388000 Sh /Rs 47.69 Cr
    * Offer for Sale  – Sh /Rs – Cr
    Face Value per share: Rs. 10
    Price Band Rs.1150-1229
    Employee discount  Rs. 0 per share
    Retail Lot Size  100 Shares
    Listing will at  NSE Sme
    Shares offered to
      Shares Rs. (Cr)
    QIB (50%) 184250
    NII  (15%) 55275
    RII  (35%) 128975
    Total Shares  368500 45.29
    Retail portion will be oversubscribed by  1290
    How much Shares to Apply in Remus Pharmaceuticals IPO?
    Min Retail Application 100 Sh Rs. 122900
    Min HNI Application  200 Sh Rs. 245800

    Who are the Promoters of Remus Pharmaceuticals IPO?

    What are the Objects of Remus Pharmaceuticals IPO?
    The Company proposes to utilize the Net Proceeds from the Issue
    1. To Meet Working Capital Requirements
    2. Funding investments for acquisitions and general corporate purposes

    IPO Tentative timetable
    IPO opens on 17 May 2023
    IPO Closes on 19 May 2023
    IPO Allotment on  24 May 2023
    Unblocking of ASBA  25 May 2023
    Credit of Shares 26 May 2023
    Listing on 29 May 2023
    Registered Office of the Company
    1101 to 1103, South Tower, One 42, B/H Ashok Vatika, Nr. Jayantilal Park BRTS, Ambli bopal Road, Ahmedabad -380054, Gujarat
     Who are the Lead Managers of Remus Pharmaceuticals IPO?
     Beeline Capital Advisors Pvt. Ltd.
    Who is the Registrar to IPO?
    Link Intime India Private Limited
    IPO Financial & Analytical Ratios
    Year Total Income Net Profit EPS RoNW Cr Cr Rs. %
    2019-20 37.61 0.27 3.49 6.75
    2020-21 73.73 0.91 11.71 18.46
    2021-22  119.78 2.05 26.45 29.43
    Book Value of the Share on 31.03.2022 Rs.149.35    
    Book Value of the Share after the IPO Rs.-    
    Offer Price   Rs. 78    
    Remus Pharmaceuticals
    Key Performance indicators
    Upper Price/last EPS ?
    Upper price/BV Ratio ?
    Upper price/BV after IPO 

    IPO Particulars & Guidance
    Peer Comparison: 
    There are no listed companies in India that engage in all aspects of the business that it operates. Accordingly, it is not possible to provide an industry comparison in relation to the Company.


    # This is only coverage of News related to Grey Market Premium & subject to rates. We do not deal in grey market premium. We do not recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.

    >>Go to Mainboard IPOs Section: Click
    >>Get Good Staff or Job, Click:
    >>Interested in Used Automobiles or vintage cars? Click:
    >>Get solid Guidance on Mutual fund Investments, Click:
    >>Study Stock Research Reports, Click:
    Interested in Crossword Puzzles? Click:

    Leave a Reply

    Your email address will not be published. Required fields are marked *